Canada Markets close in 4 hrs 43 mins
  • S&P/TSX

    19,597.92
    -71.25 (-0.36%)
     
  • S&P 500

    4,126.68
    -13.38 (-0.32%)
     
  • DOW

    32,813.60
    -18.94 (-0.06%)
     
  • CAD/USD

    0.7765
    +0.0031 (+0.4069%)
     
  • CRUDE OIL

    91.39
    +0.63 (+0.69%)
     
  • BTC-CAD

    29,749.92
    -1,569.51 (-5.01%)
     
  • CMC Crypto 200

    535.81
    -21.54 (-3.86%)
     
  • GOLD FUTURES

    1,808.60
    +3.40 (+0.19%)
     
  • RUSSELL 2000

    1,914.19
    -27.02 (-1.39%)
     
  • 10-Yr Bond

    2.7830
    +0.0180 (+0.65%)
     
  • NASDAQ

    12,496.62
    -147.84 (-1.17%)
     
  • VOLATILITY

    22.15
    +0.86 (+4.04%)
     
  • FTSE

    7,489.54
    +7.17 (+0.10%)
     
  • NIKKEI 225

    27,999.96
    -175.94 (-0.62%)
     
  • CAD/EUR

    0.7592
    +0.0001 (+0.01%)
     

Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Shareholders approved all proposed resolutions

LYON, France, June 22, 2022--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The meeting was held at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON, and was chaired by Pierre Legault, Chairman of the Board of Directors.

With a quorum of 40.787 %, the shareholders approved all the resolutions that were recommended by the Board of Directors, including the financial statements for the 2021 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the Directors, as well as delegations related to financial transactions granted to the Board of Directors.

Shareholders also approved the renewal of Pierre Legault and Janice Bourque as Board members.

Details on the voting results, as well as the presentation that was made during the meeting, will be available later today on the company’s website, in the Investors / Shareholder Info / Annual General Meeting Documents section.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive royalties and sales-based payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006105/en/

Contacts

Investor relations / Media

Aurélie Bozza
Investor Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com
+33 6 99 81 08 36

Elizabeth Woo
Senior Vice President, Investor Relations & Communication
elizabeth.woo@poxelpharma.com

NewCap
Emmanuel Huynh or Arthur Rouillé
poxel@newcap.eu
+33 1 44 71 94 94

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting